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corresponding regulatory framework, and practical considerations
for products in development from the perspective of the medical
centers.
Development of Scalable Scaffolds, Biomaterials, Matrices
J. Johnson;
Chief Scientific Officer, Columbus, OH.
Focus is shifting to the mass production of tissue engineered
scaffolds and products under appropriate regulatory requirements.
The scale-up of this translational process will help bring regenerative
medicine into the mainstream of clinical practice, but it also drives
renewed focus on how earlier research may better enable future
therapeutic applications. Manufacturing costs and sourcing of raw
materials should be factored into the product development strategy as
a critical step towards commercialization. Nanofiber Solutions, Inc.
is a regenerative medicine company developing a new class of im-
plants with unrivaled performance for the $20B soft tissue repair and
organ regeneration market. Our nanofiber technology is used to build
scaffolds that are critical in the development of life-saving tissue
engineered implants. We manufacture the world’s first nanofiber
tracheal implant which has been used successfully in four European
surgeries and are rapidly expanding our product offerings and patent
estate based on this proven scaffold technology.
Industrialization and Manufacture of Cells, Growth Factors
J. Rowley;
Chief Executive & Technology Officer, RoosterBio, Inc.,
Fredrick, MD.
Why Manufacturing Matters: How Today’s Cell Therapy Bio-
Manufacturing Innovations are Laying the Foundation for a Sus-
tainable Tissue Engineering Revolution. Technology is rapidly
moving toward the integration of biologics into products like cell
therapies, engineered tissues, bio-robotics, implantable devices, 3D
printing, food, clothing, and even toys. This coming decade will see
the incorporation of living cells into all these platforms and others not
yet imagined. To expedite this biologics revolution, inventors, de-
velopers and suppliers will require a limitless, standardized, low-cost
supply of cells - and today’s cell therapy biomanufacturing innova-
tions are laying the groundwork to make this a reality.
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Harnessing Endogenous Stem/Progenitor Cells
for Tendon Regeneration
C. Lee, Y. Jun, K. Kao;
Columbia University, New York, NY.
Tendon and ligament injuries frequently result in scar-like tissue
with poor restoration of biological structure and mechanical prop-
erties. In additional to surgical grafting by autologous or allogeneic
tissues, previous experimental work has attempted to improve ten-
don/ligament healing using growth factors, stem/progenitor cells and
biomaterials. However, these tissue-engineered grafts have encoun-
tered difficulties in clinical translation. Here we identified a rare
population (*0.8% of total tendon cells) of tendon stem/progenitor
cells (TSCs) with a perivascular origin, consistent to the previous
reports. The perivascular TSCs (PTSCs) were highly clonogenic and
multipotent. Interestingly, the PTSCs are selectively enriched up to
*20 fold by treatment with connective tissue growth factor (CTGF).
In addition, CTGF-treated PTSCs readily differentiated into teno-
cyte-like cells as evidenced by significant increases in tendon related
gene expressions as compared to the other tendon cells. In a patellar
tendon (PT) full-transection model, the number of PTSCs drastically
increased in the early phase of CTGF-delivered tendon healing (2* 7
days) in contrast to control. The PTSCs then underwent differentia-
tion into SCX+ /COL-I + tenocyte-like cells in the later healing
phase ( > 7 days) in the CTGF-delivered tendon that consequently led
to scar-less tendon healing, featured by highly organized collagen
fibrils, normal level of cellularity and mechanical properties. Initial
signaling study using siRNA knockdown showed that CTGF-induced
proliferation and tenogenic differentiation of PTSCs were regulated
via FAK and ERK1/2 signaling pathways. Our approach for tendon
regeneration by harnessing regenerative capacity of host stem/
progenitor cells requires no cell transplantation, and may offer an
alternative approach for endogenous regeneration.
Advancing Tendon Regeneration through the Development
of Bio-stimulating Tissue Engineering Approaches
M. Gomes1,2;
1University of Minho, Guimaraes, PORTUGAL, 2PT Government
Associate Laboratory, Braga/Guimaraes, PORTUGAL.
Tendon tissue engineering (TE) requires tailoring scaffolds de-
signs and properties to the anatomical and functional requirements of
tendons located in different regions of the body. Cell sourcing is also of
utmost importance as tendon cells are scarce. Recently, we have found
that it is possible to direct the tenogenic differentiation of Amniotic
fluid and Adipose tissue derived stem cells (hAFSCs and hASCs), and
also that there are hASCs subpopulations that might be more prone to
tenogenic differentiation. Nevertheless, biochemical stimulation may
not be enough to develop functional TE substitutes for a tissue that is
known to be highly dependent on mechanical loading.
These findings trigger our interest on in vitro biomechanically-
stimulating culture environments that can be achieved modulating
the scaffold architecture and composition and the stem cells. Parti-
cularly, the incorporation of magnetic nanoparticles (MNPs) within
3D constructs constitutes a novel and attractive strategy towards the
development of magnetically-responsive system that may eventually
combine therapeutic and diagnostic functionalities. An additional
advantage is that cells naturally respond to magnetic forces, and
consequently, the application of a magnetic field may enhance cell
biological performance, and ultimately stimulate cell proliferation
and differentiation. This work reports on recent studies concerning
the development of specific scaffolds architectures based on various
polymers, doped with MNPs and fabricated by either rapid proto-
typing technologies or electrospinning, enabling responsive systems
for culturing stem cells, stimulating their tenogenic differentiation.
Assessment of Tenogenic Induction by Extracellular Tendon
Matrix and Cyclic Stretching
J. Burk1, A. Aldag1, W. Brehm1, S. Heller2, B. Pfeiffer1, C. Kasper3;
1Large Animal Clinic for Surgery, University of Leipzig, Leipzig,
GERMANY, 2Department of Pathology and Laboratory Medicine,
Tulane University, New Orleans, LA, 3Institut fu¨r Biotechnologie,
BOKU Vienna, Vienna, AUSTRIA.
Treatment of tendon injuries with multipotent mesenchymal
stromal cells (MSC) led to encouraging results in animals. However,
there is still only limited understanding of the mechanisms under-
lying the beneficial effects of locally appliedMSC on tendon healing.
Tenogenic differentiation induced by the natural tendon envi-
ronment, accompanied by synthesis of important matrix components,
could be part of the complex mechanisms.
The aim of this study was to investigate this hypothesis using a
new in vitro model system, which allowed combining the use of
tendon matrix scaffolds and the application of cyclic strain, imitating
crucial natural stimuli.
Adipose-derived MSC from equine donors were seeded on decel-
lularized tendon scaffolds and once subjected to mechanical stimula-
tion with increasing stress-rest-periods. 4, 8 and 24 h post stimulation,
sampleswere assessed regarding theirmorphology, cell alignment, and
integration and expression of musculoskeletal markers.
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